Lip, G., Keshishian, A., Kamble, S., Pan, X., Mardekian, J., Horblyuk, R. and Hamilton, M. (2016) Real-World Comparison of Major Bleeding Risk among Non-Valvular Atrial Fibrillation Patients Initiated on Apixaban, Dabigatran, Rivaroxaban, or Warfarin. Thrombosis and Haemostasis, 115, 975-986.
https://doi.org/10.1160/TH16-05-0403

has been cited by the following article:

• TITLE: Deciding the Gold Standard for Oral Anticoagulation Therapy

  AUTHORS: Josh Fenn

  KEYWORDS: Oral Anticoagulation, NOAC, VKA, Gold Standard, Rivaroxaban, AC Therapy

  JOURNAL NAME: World Journal of Cardiovascular Diseases, Vol.13 No.3, March 31, 2023

  ABSTRACT: Healthcare practitioners have many anticoagulant options for treating various disease states pertaining to blood clots and blood clot formation. Each anticoagulant has pros and cons and the decision of which pharmacological agent to use can be confusing and difficult. In years past, Vitamin K antagonists have been the standard of care when treating specific disease states such as atrial fibrillation and venous thromboembolism based on habit and cost of care. The emergence of newer anticoagulants should be considered the new standard of care based on the evidence presented over the last several years.